Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection

Conclusions
In patients with non-cirrhotic CHB, JNJ-56136379+NA showed pronounced reductions in HBV DNA and HBV RNA, limited HBsAg or HBeAg declines in patients who are NCT HBeAg positive, and was well tolerated, but no clear benefit with regards to efficacy of JNJ-56136379 over NA was observed.

Source: Gut - June 7, 2023 Category: Gastroenterology Authors: Janssen, H. L. A., Hou, J., Asselah, T., Chan, H. L. Y., Zoulim, F., Tanaka, Y., Janczewska, E., Nahass, R. G., Bourgeois, S., Buti, M., Lampertico, P., Lenz, O., Verbinnen, T., Vandenbossche, J., Talloen, W., Kalmeijer, R., Beumont, M., Biermer, M., Shuk Tags: Open access, Gut Hepatology Source Type: research